Belite Bio, Inc American Depositary Shares (BLTE)
- Headquarters
- United States
- Employees
- 41
- Market Cap
- $6.4B
About Belite Bio, Inc American Depositary Shares
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
SentiSense also tracks daily options readings for Belite Bio, Inc American Depositary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Belite Bio, Inc American Depositary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.